cyrilzakka/clinical-trials huggingface dataset:
Lumbopelvic Biomechanical Variables and TMJ Kinematics Changes in Pregnant Women: A Case-Control Study

The relationship between the pelvis and stomatognathic system:

Various rationales for the relationship between the spine or pelvis and TMJ have been found. These theories include fascial, myological interrelationships, referred pain patterns and facilitating tonic neck reflexes involving inter segmental spinal pathways. A contributing mechanism could be the relationship between how TMJ occlusion, head position and body posture relate to the body's natural neurological visual/vestibular righting mechanism (Blum, 2004).

There is a Correlation between the facial axis together with the lordotic angle and the pelvic inclination, the inner gonial angle and the mandibular plane with the lordotic angle and the pelvic inclination, as well as the facial depth with the pelvic inclination showed a significant correlation (Carsten et al., 2007).


Eligibility Criteria:
Inclusion Criteria:

* The age of the participants will be ranged from 20 to 40 years. Their body mass index will be ranged from 20 to 25 kg/m2. They will have regular menstrual cycle. They will not receive any hormonal therapy or taking any regular drugs.

Exclusion Criteria:

* Bone disease. Discogenic state with radiculopathy or not. Systemic disease of musculoskeletal system. Any sensory problems. Previous vertebral fractures. Major spinal structural abnormality. Major jaw abnormality. Any jaw orthotics or prosthesis. Missing teeth.
Does Moderate Physical Activity in Hemodialysis Patients Reduce Inflammation?

The purpose of this study is to observe a potential benefit of moderate physical activity by using bed mounted cycles during hemodialysis treatment sessions on inflammatory markers in the blood of patients with end-stage renal disease (ESRD).

Patients with ESRD on chronic hemodialysis patients frequently have elevated markers of inflammation (e.g., serum CRP values) and accumulation of proinflammatory monocyte populations in the circulation. The level of inflammation is highly predictive for cardiovascular disease and mortality. Physical activity has been shown to improve dialysis efficacy by improving the elimination of retention solutes. In healthy individuals, sports activity influences inflammatory immune parameters. The study will observe the influence of moderate physical activity (using a bed mounted cycle for 30min during dialysis thrice weekly) on circulating monocyte subpopulations and inflammatory proteins over a 9 month period in 16 chronic hemodialysis patients.

Eligibility Criteria:
Inclusion Criteria:

* chronic hemodialysis treatment for at least three months
* three dialysis sessions per week
* good general clinical condition
* stable hemodynamics during the most recent three dialysis sessions

Exclusion Criteria:

* conditions making the patient unable to use the bed mounted cycle (amputations, joint disease etc)
* clinically obvious acute infections
* active malignancy
* pathologic results of spiroergometry or echocardiography that imply an elevated risk of participation
* myocardial infarction within the last 12 weeks
* uncontrolled arterial hypertension
* uncontrolled diabetes mellitis with frequent hypoglycemia
* unability to understand and consent the protocol
Airway Clearance Using High Frequency Chest Wall Oscillation

High frequency chest wall oscillation (HFCWO) has been shown to increase tracheal mucous clearance compared with control. These observations led to the development of 'The Vest' which is a non-stretchable jacket connected to an air-pulse generator and worn by the patient over the chest wall. The generator rapidly inflates and deflates 'The Vest' which gently compresses and releases the chest wall between 5 and 20 times per second. This generates mini-coughs which are said to dislodge mucus from the bronchial walls and to facilitate its movement up the airways. In addition 'The Vest' has been shown to reduce the viscosity of mucus and this should further enhance mucous clearance. The technique has, for many years, been widely used in the United States of America as an alternative to the European airway clearance regimens of the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure and oscillating positive expiratory pressure, but 'The Vest' has only recently been registered for use in Europe. It is important that the airway clearance regimen of 'The Vest' be compared with the alternative airway clearance regimens widely used in Europe.

Hypothesis: In people with cystic fibrosis 'The Vest' will lead to the expectoration of an increased weight of sputum during treatment sessions compared with alternative airway clearance regimens.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of cystic fibrosis
* 16 years of age or over
* forced expiratory volume in one second greater than or equal to 25 percent of predicted
* hospitalised patients in a stable clinical state

Exclusion Criteria:

* current severe haemoptysis
* rib fractures
* pregnancy
* inability to give consent
Nerve Transfers in Post-stroke Spasticity

Stroke is nowadays a leading cause of disability with devastating sequelae. Upper limb spasticity is one of them. Nevertheless, not all the muscles are equally affected, as some may turn spastic or paretic and other remain intact. This unique pathophysiological mosaic dictates a precise therapeutic plan. Existing spasticity treatment has significant drawbacks due to its unspecific targeting and short duration. A causal, life-lasting treatment, precisely adapted to every single patient's needs and to disease pattern, is currently missing. Hyperselective muscle denervation and subsequent cognitive reinnervation with appropriate unaffected donor nerves may break the pathological spastic circuit and provide volitional muscle control. With this pioneering study we will perform cognitive nerve transfers to spastic muscles and will prospectively investigate their effects on clinical, electrophysiological, molecular-biological and histological level. Accurate donor nerve selection will be for the first time quantified through motor unit number estimation with high-density needle electromyography. This revolutionary concept can open the window to a new era of therapeutic possibilities for stroke victims.


Eligibility Criteria:
Inclusion Criteria:

* Are undergoing nerve transfers
* Age from 18 to 75 years old
* Minimum of 1 year interval after stroke
* Are able to understand German or English
* Medical Research Council (MRC) Muscle scale for donor nerves: M4 or M5
* Walking patients, with or without crutches
* Good general health condition and social support

For the control group:

* Age 18-75 years old
* Indication for ulnar nerve release and submuscular transposition for compression neuropathy in the elbow
* No other neurological disorders

Exclusion Criteria:

* Stroke earlier than 3 years at the time of first consultation
* Lower limb spasticity and patients mobile with wheel chair
Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

To investigate the effect of the P-gp inducer rifampicin on the pharmacokinetic parameters of nintedanib


Eligibility Criteria:
Inclusion criteria:

1. Healthy male subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma

Glaucoma is one of the most common causes of blindness in the industrialized nations. For a long time glaucoma has been defined as a disease in which high intraocular pressure (IOP) leads to irreversible optic disc damage and subsequent visual field loss. However, recent investigations show that IOP is not the only factor that is involved in the glaucomatous process leading to retinal ganglion cell death. The role of vascular factors in the pathogenesis of glaucoma has recently received much attention based on animal experiments and epidemiological studies. It is, however, assumed that vascular factors do not contribute to same degree in all glaucoma patients. Generally, it is believed that a vascular component is more important in normal tension glaucoma patients and patients with underlying cardiovascular disease. Little is, however, known about a potential association between optic nerve head morphology and ocular perfusion in POAG patients. The current study seeks to gain insight into this association by assessing ocular blood flow parameters with a number of noninvasive technologies.


Eligibility Criteria:
Inclusion Criteria:

* Men and women over 18 years
* Unilateral or bilateral primary open angle glaucoma
* At least 3 reliable visual field tests showing CPSD \>= 2.0 in the eye that will be studied

Exclusion Criteria:

* History of acute angle closure
* Closed or barely open anterior chamber angle
* Standard deviation of visual field testing \> 10
* Intraocular surgery or argon laser trabeculoplasty within the last six months
* Ocular inflammation or infection within the last three months
* Topical or systemically/oral therapy with steroids
Analgesic Effect of Laser Therapy in Children

Pain management after tonsillectomy could be challenging, with different protocols and various outcome depending on individual patient; moreover, odynophagia due to surgery can, in extreme cases, lead to block oral fluid intake, ending in dehydration and thus hospitalization. A small pilot study demonstrated efficacy of photo-biomodulation (PBM) in managing pain after tonsillectomy and it suggests that PBM can be included in clinical practice. The present research aims to confirm and expand the findings from this study, being the first step in including PBM in clinical routine after tonsillectomy. Use of this treatment, which is non-damaging, non-toxic and easy to supply to patients, could greatly improve individual quality of life after a surgical treatment; its use in the clinical practice could represent an advantage for the institute, leading to more patients' satisfaction, due to the lower pain sensation after surgery and quicker recovery time.


Eligibility Criteria:
Inclusion Criteria:

Tonsillectomy or adenotonsillectomy due to apneic chronic snoring and/or obstructive sleep apnea and/or recurrent tonsillitis

Exclusion Criteria:

1. American Society of Anesthesiologists (ASA) Score \> 2
2. Neuropsychiatric co-morbidity
3. Pro-hemorrhage coagulation disorders
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients with stage IIB, stage III, or stage IV AIDS-related Hodgkin's disease.

OBJECTIVES:

* Determine the objective response rate, response duration, and survival of patients receiving lomustine/etoposide/cyclophosphamide/procarbazine (CECP) for stage IIB-IV AIDS-related Hodgkin's disease.
* Assess the feasibility and toxic effects of CECP in this patient population.

OUTLINE: Patients receive oral lomustine on day 1, oral etoposide on days 1-3, and oral cyclophosphamide and procarbazine on days 22-31. Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42. The course is repeated every 6 weeks.

Patients with a complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course. Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy. Patients failing to respond after 1 course are removed from the study.

Patients will be followed every 3 months until death.

PROJECTED ACCRUAL: A minimum of 16 evaluable patients will be accrued.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically proven stage IIB-IV AIDS-related Hodgkin's disease

  * Patients with Hodgkin's disease as the only HIV-related condition must have a positive ELISA for HIV confirmed by Western Blot
* Measurable or evaluable disease
* No cytologic or radiologic evidence of CNS involvement

PATIENT CHARACTERISTICS:

Age:

* Any age

Performance status:

* ECOG 0-3

Life expectancy:

* At least 6 weeks

Hematopoietic:

* WBC at least 1,500/mm3
* Platelet count at least 50,000/mm3

Hepatic:

* Bilirubin no greater than 3.0 mg/dL

Renal:

* Creatinine no greater than 3.0 mg/dL

Other:

* Active infection is allowed (provided prognosis is estimated to be at least 6 weeks)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* No prior chemotherapy for Hodgkin's disease
* At least 4 weeks since chemotherapy for Kaposi's sarcoma

Endocrine therapy:

* Not specified

Radiotherapy:

* Prior radiotherapy for localized stage I or II disease that has progressed beyond initial radiation ports is allowed

Surgery:

* Not specified

Other:

* Concurrent AZT therapy is allowed
Spironolactone Improved Children With NCOR Mutations

NCOR1/2 constitutes the NCOR complex, which interacts with many different nuclear receptors to produce special physiological effects. These receptors further recruit epigenome modifying enzymes that are involved in the transcription of multiple genes involved in neurotransmission and synaptic plasticity. Studies of mice with gene knockout and autistic patients with NCOR mutations have found that both exhibit clinical symptoms characteristic of ASD, such as deficits in social interaction, spatial learning and impaired recognition memory. Further study revealed that the cause was the hyperexcitability of GABaergic neurons in the lateral hypothalamus (LH) due to the NCOR1/2 defect, which impaired synaptic plasticity in the hippocampal CA3 region through the single synaptic LHGABA-CA3 neural projection, and thus exhibited learning/memory impairment. Therefore, drugs that affect the NCOR receptor can improve learning/memory impairment by affecting GABA neurons. Spironolactone is a widely used diuretic with good safety. It is widely used in the treatment of hypertension, edema and anti-androgen therapy in children. In this study, spironolactone is one of the most popular drugs used to treat children with NCOR gene mutation. In our previous animal experiments, we found that spironolactone could treat NCOR mutant mice and improve ASD-related symptoms, such as reduced sensorimotor capacity, learning disability and impaired working memory; Moreover, the efficacy of related diuretics in the treatment of ASD diseases has been proved clinically. So spironolactone may be a new target for the treatment of NCOR patients in the future.


Eligibility Criteria:
Inclusion Criteria:

1. ADOS-2 diagnostic criteria for autistic children
2. Patients with NCOR1/2 gene mutation detected by whole exon test;
3. Age: 3-10 years old;
4. The subject and (or) guardian sign the informed consent, agreeing that the researcher will cooperate with the clinical trial process and collect clinical data and peripheral blood and urine samples;

Exclusion Criteria:

1. have other pathogenic mutations (confidence higher than the NCOR1/2 mutation);
2. Boys over 10 years old;
3. Allergic to spironolactone, used spironolactone one month before enrollment;
4. Hyperkalemia, serum potassium concentration \> 5.5mmol/L;
5. Renal insufficiency;
6. Used related drugs one month before enrollment: potassium supplement, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, digoxin, coletenamine, acetylsalicylic acid, abiraterone;
7. Fever (body temperature above 37.3°);
8. Clinically significant metabolic, hematological, liver, immune, urological, endocrine, neurological, pulmonary, psychiatric, skin, allergic, renal, or other major conditions in the determination of ASD that may affect the interpretation of study findings or patient safety.
Neurofilament Assay for the Diagnosis of ALS

The aim of the study is to evaluate the interest of the determination of pNFH and NFL neurofilaments in serum for the diagnosis of ALS in patients with a diagnostic standoff after evaluation in an expert ALS center. The hypothesis is that one of these biomarkers, or their combined analysis, will make it possible to confirm or invalidate the diagnosis of ALS.

For this study, which aims to evaluate a test to help in the diagnosis of ALS that could be integrated into routine practice, it was preferred to use blood tests. Blood sampling is significantly less invasive than CSF sampling, and more easily generalized, including in ambulatory conditions.

Eligibility Criteria:
Inclusion criteria :

Subjects with first and/or second motor neuron disease, evolving clinically and/or electrically over at least 12 months, not meeting the diagnostic criteria for ALS (revised El Escorial criteria):

* Isolated peripheral motor neuron disease (at least one region of the PNM) OR
* Isolated central motor neuron involvement (at least two areas of the MNC) OR
* associated involvement of the MNP and MNC but in the presence of an associated pathology responsible for a persistent diagnostic doubt (double narrow cervical and lumbar canal, associated evolving cancer evoking a paraneoplastic syndrome without specific antibody found) Age superior to 18 years Management and follow-up in one of the French ALS centers Patient able to express his non-opposition Affiliation with social security or beneficiary of such a plan

Non-inclusion criteria:

Refusal of the patient Person under a legal protection measure (guardianship, curatorship or safeguard of justice).

Person deprived of liberty by judicial or administrative decision.
Acromio-clavicular Dislocation Type III - Conservative Treatment Versus Surgical Hook Plate Treatment

Acromio-clavicular (AC) joint dislocation corresponds to 8.6% of all joint dislocations and represents a major injury to the shoulder girdle. The nature of the treatment is decided according to the severity of the lesion.

The purpose of this study is to determine whether the surgical treatment is required or not for type III AC joint dislocations.


Eligibility Criteria:
Inclusion Criteria:

* men or women ≥ 18 years-old;
* AC joint dislocation type III with Zanca X-ray view demonstrating CC distance of 200%;
* trauma-surgery delay of less than 14 days;
* consent form signed.

Exclusion Criteria:

* AC joint dislocation type I, II, IV, V or VI;
* associated neuro-vascular damage;
* men or women \> 60 years-old;
* open dislocation;
* local skin damage;
* dislocation in a polytrauma patient;
* floating shoulder;
* fracture of the ipsilateral or controlateral arm or shoulder girdle;
* fracture of the coracoid process of the scapula;
* history of previous surgery to the shoulder;
* medical condition preventing surgery;
* men or women unfit to consent;
* any other condition that make the examinator thinks that the follow up would be problematic.
Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer

This is a randomized, open-label, active comparator-controlled trial of subjects with advanced (Barcelona stage B/C) hepatocellular carcinoma. Subjects will be receive one treatment with Trans-Arterial Chemo-Embolization (TACE) prior to randomization. Subsequently, subjects will be randomized to observation or, if indicated, up to an additional TACE treatments, or to Stereotactic Body Radiotherapy (SBRT). Tumor response following interventions will be evaluated at three months.


Eligibility Criteria:
Inclusion Criteria:

* Hepatocellular carcinoma (Barcelona Stage B or C)
* Treatment with Stereotactic Body Radiosurgery can occur within 6 weeks of enrollment
* Age ≥ 18 years and ≤ 70 years
* Eastern Cooperative Oncology Group Performance status ≤ 2
* Patient has a) Radiographic enhancing liver lesions with early wash out on triple phase CT or MRI or b) histological confirmation of HCC as determined by the Liver Tumor Board
* Hemoglobin \> 10.0 g/dL
* Total bilirubin \> 3.0 mg/dL
* AST (SGOT) ≤ 3x institutional upper limit of normal
* ALT (SGPT) ≤ 3x institutional upper limit of normal
* Absolute neutrophil count ≥ 1,500/μl
* Platelet count ≥ 50,000/μl (may be post-transfusion if clinically indicated)
* Aggregate maximal dimension of liver tumors ≤ 8 cm
* Cirrhosis classified as Child Pugh Class A or B (score ≤ 7)
* Determined by the treating physician to be medically eligible for liver transplantation measured by imaging modality (MRI/CT scan) three months post final treatment
* Life expectancy ≥ 12 weeks
* Ability to understand study and provide legally effective written informed consent
* Women of child-bearing potential must have a negative test within 4 weeks to the start of the SBRT treatment and must not be pregnant or nursing a child
* Sexually active women must agree to use accepted forms of birth control throughout the study, which include abstinence, oral contraceptives (birth control pills), IUD, diaphragm with spermicide, Norplant, hormone injections, condoms with spermicide, or documentation of medical sterilization

Exclusion Criteria:

* History of abdominal radiation
* Cirrhosis classified as Child Pugh Class B with score ≥ 8
* Prior invasive malignancy other than primary liver malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
* Evidence of metastatic disease prior to registration
* Evidence of main portal vein thrombosis
* History of cardiac ischemia or stroke within 6 months prior to enrollment
* Any concurrent medical or psychosocial condition that prohibits a major surgical procedure or immunosuppressant that would constitute a contraindication to liver transplantation
* History of sorafenib therapy within 21 days prior to enrollment
Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy

The purpose of this study is to evaluate the interest of enthesis sonography for the diagnosis of spondylarthritis, in patients with uncertain diagnosis consulting for clinical symptoms suggestive of spondylarthritis

Spondylarthritis (SPA) are the second most frequent inflammatory rheumatic disorders and, because it starts early in life and has a chronic progressive course, the impact of this disease on health resources and patient's life quality can be important. Because the characteritic signs of SPA, like radiological evidence of sacro-iliitis, appear late in time, the lag time between the onset first signs of SPA for the patient and the confirmed diagnosis can be very long (up to 8 years). Previous studies proved that patients who are affected by SPA are showing abnormal vascularization of peripheral enthesis more frequently than patients affected by other rheumatic diseases. Ultrasonography in B mode combined with power Doppler (PDUS) is a non invasive and highly sensitive toll which can detect enthesitis and abnormal vsacularization even for the patients who are not showing yet the evidence of SPA's symptomatology. Using PDUS as a early diagnosis tool could lead to the improvement of diagnostic procedures and therapeutic management of SpA and reduce the cost of diagnosis for patient and health insurances.

Eligibility Criteria:
Inclusion Criteria:

* patients \< 50 years old, consulting for spinal inflammatory symptoms \> 3 months duration
* patients consulting for arthritis or tenderness joints \> 3 months duration
* patients \< 50 years old consulting for enthesitis or dactylitis \> 3 months duration
* patients with uveitis and HLA-B27 positivity
* relatives of SpA patients consulting for symptoms suggestive of SpA

Exclusion Criteria:

* patient with confirmed diagnosis of rheumatic disease (included SpA)
* patient protected by law (patient \<18 years old, pregnant woman)
* patient who can't atempt the RMI
* patient who will have difficulties to complete the two years of follow-up